Details of Drug-Drug Interaction
| Drug General Information (ID: DDIC7IPSBL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Digoxin | Drug Info | Vincristine (liposome) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiarrhythmic Agents | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Digoxin-Vincristine (liposome) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered intestinal mucosa Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Digoxin | Vincristine (liposome) | |||||||
| Mechanism | Absorption affected by changes in intestinal mucosa | Alteration of intestinal mucosa | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Intestinal mucosa | ||||||||
| Factor Description | Intestinal mucosal barrier function is the ability of the intestine to adequately contain microorganisms and molecules in the lumen while maintaining the ability to absorb nutrients. The absorption of drugs may be altered when the intestinal mucosa is disrupted. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Digoxin serum levels and effectiveness should be monitored closely following the initiation or discontinuation of antineoplastic agents, and the dosage adjusted as necessary. | ||||||||

